RHYTHM PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Increase (Decrease) in Deferred Revenue of -$194.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$49.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$145.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $194.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2025 was -$1.09M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2024 was $0.00.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2023 was -$148.00K.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$6.61M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$194.00K 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$145.00K 10-Q · filed 2026-05-05 | $49.00K derived: sum of 2 quarters · filed 2026-05-05 | $49.00K derived: sum of 3 quarters · filed 2026-05-05 | $49.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $194.00K derived: sum of 2 quarters · filed 2026-02-26 | $194.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.09M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | -$1.29M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.29M 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | -$1.29M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$142.00K derived: sum of 3 quarters · filed 2026-02-26 | -$148.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$142.00K derived: sum of 2 quarters · filed 2024-11-06 | -$148.00K 10-Q · filed 2024-11-06 | -$7.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$148.00K 10-Q · filed 2024-08-06 | -$7.23M derived: sum of 3 quarters · filed 2025-02-28 | -$7.78M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$6.00K 10-Q · filed 2024-05-07 | -$7.09M derived: sum of 2 quarters · filed 2025-02-28 | -$7.63M derived: sum of 3 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$7.63M derived: sum of 2 quarters · filed 2025-02-28 | -$6.61M 10-K · filed 2025-02-28 | |
| 2022-09-30 | -$549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $474.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $1.02M 10-Q · filed 2023-08-01 | |||
| 2016-12-31 | -$178.00K derived: 8-K 12 month − 10-Q 9 month · filed 2018-11-09 | -$249.00K 8-K · filed 2018-11-09 | ||
| 2016-09-30 | -$71.00K 10-Q · filed 2017-11-14 | |||
| 2015-12-31 | $249.00K 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |